BacPROTACs mediate targeted protein degradation in bacteria

Francesca Morreale(Research Institute of Molecular Pathology), Stefan Kleine(University of Duisburg-Essen), Julia Leodolter(Research Institute of Molecular Pathology), Sabryna Junker(Research Institute of Molecular Pathology), David M. Hoi(Research Institute of Molecular Pathology), Stepan Ovchinnikov(Research Institute of Molecular Pathology), Anastasia Okun(Research Institute of Molecular Pathology), Juliane Kley(Research Institute of Molecular Pathology), R Kurzbauer(Research Institute of Molecular Pathology), Lukas Junk(Saarland University), Somraj Guha(Saarland University), David Podlesainski(University of Duisburg-Essen), Uli Kazmaier(Saarland University), Guido Boehmelt(Boehringer Ingelheim (Austria)), Harald Weinstabl(Boehringer Ingelheim (Austria)), Klaus Rumpel(Boehringer Ingelheim (Austria)), Volker M. Schmiedel(Boehringer Ingelheim (Austria)), Markus Hartl(Max Perutz Labs), David Haselbach(Research Institute of Molecular Pathology), Anton Meinhart(Research Institute of Molecular Pathology), Markus Kaiser(University of Duisburg-Essen), Tim Clausen(Research Institute of Molecular Pathology)
Cited by 180Open Access
Full Text

Abstract

Hijacking the cellular protein degradation system offers unique opportunities for drug discovery, as exemplified by proteolysis-targeting chimeras. Despite their great promise for medical chemistry, so far, it has not been possible to reprogram the bacterial degradation machinery to interfere with microbial infections. Here, we develop small-molecule degraders, so-called BacPROTACs, that bind to the substrate receptor of the ClpC:ClpP protease, priming neo-substrates for degradation. In addition to their targeting function, BacPROTACs activate ClpC, transforming the resting unfoldase into its functional state. The induced higher-order oligomer was visualized by cryo-EM analysis, providing a structural snapshot of activated ClpC unfolding a protein substrate. Finally, drug susceptibility and degradation assays performed in mycobacteria demonstrate in vivo activity of BacPROTACs, allowing selective targeting of endogenous proteins via fusion to an established degron. In addition to guiding antibiotic discovery, the BacPROTAC technology presents a versatile research tool enabling the inducible degradation of bacterial proteins.


Related Papers

No related papers found

Powered by citation graph analysis